Higher buprenorphine doses help patients stay in opioid use disorder treatment, new study finds
Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more likely to stay in treatment. Those on 17 to 24 milligrams averaged 190 days in care compared to 90 days for those on 8 milligrams or less. Yet Black patients are less likely than white patients to receive the higher doses.
Those are the key findings of a study my colleagues and I conducted with 5,000 adults enrolled in Medicaid in
I am an assistant professor at University of Pennsylvania’s
Why it matters
Buprenorphine is one of the most effective treatments for opioid use disorder. Unlike most opioids, buprenorphine only partially activates opioid receptors, providing enough stimulation to prevent withdrawal and cravings while not causing euphoria. This lowers the risk of overdose.
Buprenorphine also blocks other opioids from binding to opioid receptors and causing euphoric effects. This deters patients from using other opioids while on the medication.
Across the board, patients who received higher doses of buprenorphine – usually 17 to 24 milligrams per day, but sometimes more – stayed in treatment significantly longer than those who started on medium doses of 9 to 16 milligrams, or lower doses of 8 milligrams.
Staying in treatment for opioid use disorder is important because it reduces overdose risk and provides a foundation for recovery.
Our study also revealed racial disparities.
Black patients were less likely than white patients to receive the 17 to 24 milligram prescriptions. These differences may reflect prescriber preferences, inequities in health care or misconceptions among both patients and clinicians about safe dosing.
Other groups were more likely to receive higher buprenorphine doses. Over half of our sample was diagnosed with a musculoskeletal condition – such as osteoarthritis, rheumatoid arthritis and gout – alongside opioid use disorder. These patients were more likely to receive higher doses.
Why it matters
Over the past decade, the unregulated street opioid supply across the
Identifying disparities in buprenorphine dosing also sets up a number of interventions that insurers can use to address them.
For example,
In
Now, the FDA has removed the phrase “target dose” from the drug label. It also added that although doses over 24 milligrams have not been investigated in randomized clinical trials, they “may be appropriate for some patients.”
This clarification rolls back outdated language that many clinicians and insurers took to mean that 16 milligrams was the maximum for treating opioid use disorder.
What still isn’t known
Clinicians still do not fully understand patient preferences around buprenorphine dosing. Some patients may want higher doses to better manage withdrawal or cravings. Others may prefer lower doses due to concerns about not being able to discontinue buprenophrine if they are on a high dose.
The dosing patterns that we observed suggest that Black patients do not have equal access to higher doses of buprenorphine they may need. Understanding why these differences occur, and how to address them, is essential to equitable treatment.
The Research Brief is a short take on interesting academic work.
Read more of our stories about


Rush Co. with lowest storm damage payout in Kansas in 2025
New Data from University of Minnesota Illuminate Findings in Investment (Central Bank Reputation With Noise): Investment
Advisor News
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
More Advisor NewsAnnuity News
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
More Annuity NewsHealth/Employee Benefits News
- Medicaid work rules don’t apply to Native Americans. They could still lose coverage.
- Oscar Highlights Tailored New Health Products in Florida for 2027 Open Enrollment
- Oscar Highlights Tailored New Health Products in Texas for 2027 Open Enrollment
- States get until July to cut Medicaid coverage over work requirement
- CRUSH Rule could crush health insurance agents, industry group says
More Health/Employee Benefits NewsLife Insurance News
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
- Military Briefs: November 19-25
- California’s new solvency rules: What should life insurance advisors watch?
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
More Life Insurance News